AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12092689 — intervention group
Group type: EXPERIMENTAL
Intervention: Active therapy (twice daily insulin injections plus an annual insulin infusion)
Number of subjects: 339
Study 12092689 — intervention group
Group type: COMPARATOR
Intervention: Close observation
Number of subjects: 339
Study 12092689 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 339
Study 10048236 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills training (CST) with intensive diabetes management
Number of subjects: 77
Study 10048236 — intervention group
Group type: COMPARATOR
Intervention: Intensive diabetes management without CST
Number of subjects: 77
Study 7479201 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime plus metronidazole (1-g intravenous dose of cefotaxime plus 500-mg oral dose of metronidazole)
Number of subjects: 9
Study 7479201 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (2 g intravenous doses every 6 hours)
Number of subjects: 9
Study 7479201 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin-sulbactam (3 g intravenous doses every 6 hours)
Number of subjects: 9
Study 2185526 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril treatment
Number of subjects: 0
Study 2185526 — intervention group
Group type: COMPARATOR
Intervention: Digoxin treatment
Number of subjects: 0
Study 2185526 — intervention group
Group type: COMPARATOR
Intervention: Control period
Number of subjects: 0
Study 91837 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐pyridoxylidene glutamate (PG) scanning
Number of subjects: 116
Study 91837 — intervention group
Group type: COMPARATOR
Intervention: Oral cholecystography
Number of subjects: 116
Study 91837 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonography
Number of subjects: 116
Study 28817412 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage (MLD)
Number of subjects: 80
Study 28817412 — intervention group
Group type: EXPERIMENTAL
Intervention: Bodyflow (BF) therapy
Number of subjects: 80
Study 28817412 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep oscillation (DO) therapy
Number of subjects: 80
Study 28817412 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 27712462 — intervention group
Group type: EXPERIMENTAL
Intervention: Access therapy with PRF and 1% ALN gel (group 3)
Number of subjects: 72
Study 27712462 — intervention group
Group type: COMPARATOR
Intervention: Access therapy alone (group 1)
Number of subjects: 72
Study 27712462 — intervention group
Group type: COMPARATOR
Intervention: Access therapy with PRF (group 2)
Number of subjects: 72
Study 25565583 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150 to 300 mg/d)
Number of subjects: 203
Study 25565583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 23788068 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB)
Number of subjects: 16
Study 23788068 — intervention group
Group type: COMPARATOR
Intervention: Femoral Nerve Block (FNB)
Number of subjects: 16
Study 21377074 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.2 mg/kg
Number of subjects: 50
Study 21377074 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 50
Study 19418780 — intervention group
Group type: EXPERIMENTAL
Intervention: Community leg ulcer clinics
Number of subjects: 0
Study 19418780 — intervention group
Group type: COMPARATOR
Intervention: Home care visits
Number of subjects: 0
Study 17364153 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic transabdominal preperitoneal patch (TAPP) procedure
Number of subjects: 147
Study 17364153 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein technique
Number of subjects: 147
Study 15383196 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose 1 frovatriptan
Number of subjects: 241
Study 15383196 — intervention group
Group type: COMPARATOR
Intervention: Dose 1 placebo
Number of subjects: 241
Study 14568602 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 20
Study 14568602 — intervention group
Group type: COMPARATOR
Intervention: Interferon alpha‐2b/ribavirin
Number of subjects: 20
Study 10103339 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir monotherapy (4 mg/kg every 12 hours for 6 weeks, then 8 mg/kg every 12 hours for 6 weeks)
Number of subjects: 47
Study 10103339 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir in combination with another antiretroviral agent (8 mg/kg every 12 hours for 12 weeks)
Number of subjects: 47
Study 10103339 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir monotherapy
Number of subjects: 47
Study 7758213 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (2.8 micrograms of sodium selenite per kg per day) for 5 months
Number of subjects: 27
Study 7758213 — intervention group
Group type: COMPARATOR
Intervention: Placebo control for 5 months
Number of subjects: 27
Study 7758213 — intervention group
Group type: COMPARATOR
Intervention: Selenium supplementation and Placebo control
Number of subjects: 27
Study 2108254 — intervention group
Group type: EXPERIMENTAL
Intervention: Na2 ethylene diamine tetra acetic acid (EDTA) plus MgSO4, B complex, and vitamin C
Number of subjects: 10
Study 2108254 — intervention group
Group type: COMPARATOR
Intervention: Placebo of MgSO4, B complex, and vitamin C in Ringer's lactate solution
Number of subjects: 10
Study 2108254 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA after initial placebo treatment
Number of subjects: 10
Study 44182 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoperidine
Number of subjects: 0
Study 44182 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia
Number of subjects: 0
Study 31714582 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine
Number of subjects: 134
Study 31714582 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin
Number of subjects: 134
Study 30646801 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2170
Study 30646801 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 2170
Study 30646801 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 2170
Study 28910196 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpinia galanga proprietary extract (E-AG-01)
Number of subjects: 59
Study 28910196 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Alpinia galanga (E-AG-01) with caffeine
Number of subjects: 59
Study 28910196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 26017535 — intervention group
Group type: COMPARATOR
Intervention: FroDex 37.5 (early intake)
Number of subjects: 314
Study 26017535 — intervention group
Group type: COMPARATOR
Intervention: FroDex 37.5 (late intake)
Number of subjects: 314
Study 26017535 — intervention group
Group type: COMPARATOR
Intervention: FroDex 25 (early intake)
Number of subjects: 314
Study 26017535 — intervention group
Group type: EXPERIMENTAL
Intervention: Frova (early intake)
Number of subjects: 314
Study 26017535 — intervention group
Group type: COMPARATOR
Intervention: Frova (late intake)
Number of subjects: 314
Study 24322060 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) prevention system
Number of subjects: 4407
Study 24322060 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4407
Study 22801247 — intervention group
Group type: COMPARATOR
Intervention: Triple oral therapy (metformin, glyburide, and pioglitazone)
Number of subjects: 16
Study 22801247 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and metformin
Number of subjects: 16
Study 22801247 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and metformin (initial therapy)
Number of subjects: 16
Study 22801247 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups (triple oral therapy and insulin/metformin)
Number of subjects: 16
Study 22801247 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-based treatment
Number of subjects: 16
Study 20021599 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week mindfulness meditation program
Number of subjects: 40
Study 20021599 — intervention group
Group type: COMPARATOR
Intervention: 8-week education control program
Number of subjects: 40
Study 18090191 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom management (SM) intervention
Number of subjects: 40
Study 15141793 — intervention group
Group type: COMPARATOR
Intervention: Bag-valve device
Number of subjects: 104
Study 15141793 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxylator (manual and automatic modes)
Number of subjects: 104
Study 11226823 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanfast (Julphar, UAE)
Number of subjects: 0
Study 11226823 — intervention group
Group type: COMPARATOR
Intervention: Lanzor (Laboratoires Houde, Paris, France)
Number of subjects: 0
Study 9541446 — intervention group
Group type: EXPERIMENTAL
Intervention: Fucithalmic single unit dose eye drops
Number of subjects: 144
Study 9541446 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol eye ointment
Number of subjects: 144
Study 8031107 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonnutritive sucking (NNS) using a pacifier immediately after crying was induced by a heelstick.
Number of subjects: 59
Study 8031107 — intervention group
Group type: COMPARATOR
Intervention: Control group (ONNS) infants who did not receive NNS.
Number of subjects: 59
Study 31553201 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0
Study 31553201 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 31553201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29146604 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 32
Study 29146604 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 32
Study 25371402 — intervention group
Group type: EXPERIMENTAL
Intervention: Health management program
Number of subjects: 8217
Study 25371402 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 8217
Study 24148616 — intervention group
Group type: EXPERIMENTAL
Intervention: IV 3% saline
Number of subjects: 26
Study 24148616 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 3% saline
Number of subjects: 26
Study 24148616 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 26
Study 23062548 — intervention group
Group type: EXPERIMENTAL
Intervention: rHFSC (recombinant human hyaluronidase-facilitated subcutaneous rehydration)
Number of subjects: 148
Study 23062548 — intervention group
Group type: COMPARATOR
Intervention: IV (intravenous rehydration)
Number of subjects: 148
Study 23062548 — intervention group
Group type: EXPERIMENTAL
Intervention: rHFSC
Number of subjects: 148
Study 23062548 — intervention group
Group type: COMPARATOR
Intervention: IV
Number of subjects: 148
Study 19541916 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AEX)
Number of subjects: 38
Study 19541916 — intervention group
Group type: COMPARATOR
Intervention: Stretching Exercise (SE)
Number of subjects: 38
Study 17122613 — intervention group
Group type: EXPERIMENTAL
Intervention: Early laparoscopy (LAP)
Number of subjects: 135
Study 17122613 — intervention group
Group type: COMPARATOR
Intervention: Clinical observation (OBS)
Number of subjects: 135
Study 15275765 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg
Number of subjects: 120
Study 15275765 — intervention group
Group type: COMPARATOR
Intervention: Oxazepam 15 mg (active placebo)
Number of subjects: 120
Study 11420167 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose aprotinin (20,000 IU/kg as pretreatment followed by 7500 IU/kg for 6 h)
Number of subjects: 20
Study 11420167 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 20
Study 11420167 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose aprotinin
Number of subjects: 20
Study 9240302 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm cardiopulmonary bypass (36 degrees C)
Number of subjects: 62
Study 9240302 — intervention group
Group type: COMPARATOR
Intervention: Cold cardiopulmonary bypass (28 degrees C)
Number of subjects: 62
Study 12959274 — intervention group
Group type: EXPERIMENTAL
Intervention: BRL 35135 8 mg
Number of subjects: 8
Study 12959274 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 8
Study 12959274 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 20 mg (N20) + BRL 35135 8 mg
Number of subjects: 8
Study 3549173 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitolterol mesylate 1.0 mg
Number of subjects: 6
Study 3549173 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitolterol mesylate 0.5 mg to 3.0 mg
Number of subjects: 6
Study 3549173 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitolterol mesylate >1.0 mg
Number of subjects: 6
Study 3549173 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitolterol mesylate (general)
Number of subjects: 6
Study 27402135 — intervention group
Group type: EXPERIMENTAL
Intervention: PocketCPR application
Number of subjects: 118
Study 27089542 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A (BTX) treatment with calf muscle injections every 6 months if needed
Number of subjects: 30
Study 27089542 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (CO) consisting of firm shoes, night splints, home stretching program, and physiotherapy
Number of subjects: 30
Study 27089542 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A (BTX) treatment
Number of subjects: 30
Study 27089542 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (CO)
Number of subjects: 30
Study 24225356 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month lipid-based nutrient supplement (LNS) providing 108 kcal and other nutrients including vitamin A, vitamin B-12, iron, and zinc at ≥80% of the recommended amounts
Number of subjects: 589
Study 24225356 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month lipid-based nutrient supplement (LNS)
Number of subjects: 589
Study 24225356 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 589
Study 21869764 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restricted diet with resistance training (RT)
Number of subjects: 92
Study 21869764 — intervention group
Group type: COMPARATOR
Intervention: Caloric restricted diet without resistance training (RT)
Number of subjects: 92
Study 21869764 — intervention group
Group type: EXPERIMENTAL
Intervention: Bertin index (DXA)
Number of subjects: 92
Study 21869764 — intervention group
Group type: COMPARATOR
Intervention: CT scan
Number of subjects: 92
Study 21869764 — intervention group
Group type: EXPERIMENTAL
Intervention: Bertin index and CT scan
Number of subjects: 92
Study 21869764 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat mass and lean body mass
Number of subjects: 92
Study 20684825 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment after PCI
Number of subjects: 238
Study 20684825 — intervention group
Group type: COMPARATOR
Intervention: Hypo-adiponectinemia at baseline
Number of subjects: 238
Study 18155287 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 0
Study 18155287 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Transtheoretical Model (TTM)
Number of subjects: 0
Study 18155287 — intervention group
Group type: COMPARATOR
Intervention: Health Risk Intervention (HRI)
Number of subjects: 0
Study 15774905 — intervention group
Group type: EXPERIMENTAL
Intervention: High saturated fat (SFA) diet
Number of subjects: 40
Study 15774905 — intervention group
Group type: COMPARATOR
Intervention: Low-fat, high-carbohydrate (CARB) diet
Number of subjects: 40
Study 15774905 — intervention group
Group type: COMPARATOR
Intervention: High monounsaturated fat (MUFA) diet
Number of subjects: 40
Study 15774905 — intervention group
Group type: COMPARATOR
Intervention: High polyunsaturated fat (PUFA) diet
Number of subjects: 40
Study 14629243 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (25 mg per day, with increments to a maximum of 100 mg per day)
Number of subjects: 36
Study 10622518 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning trial
Number of subjects: 20
Study 10622518 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening trial
Number of subjects: 20
Study 10622518 — intervention group
Group type: EXPERIMENTAL
Intervention: Average minimum intensity
Number of subjects: 20
Study 7795149 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g fish-oil concentrate per day
Number of subjects: 511
Study 7795149 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fish oil)
Number of subjects: 511
Study 2029123 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediazole (ES) - 50 mg/kg + 150 mg/kg sulfamide, given in three divided doses for ten days
Number of subjects: 106
Study 2029123 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor - 40-50 mg/kg, given in three divided doses for ten days
Number of subjects: 106
Study 7025475 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzafibrate
Number of subjects: 29
Study 7025475 — intervention group
Group type: COMPARATOR
Intervention: Clofibate
Number of subjects: 29
Study 31235418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lipid lowering (target LDL-C <70mg/dL)
Number of subjects: 150
Study 31235418 — intervention group
Group type: COMPARATOR
Intervention: Conventional lipid lowering (target LDL-C ≥70mg/dL, <128mg/dL)
Number of subjects: 150
Study 31235418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lipid lowering
Number of subjects: 150
Study 31235418 — intervention group
Group type: COMPARATOR
Intervention: Conventional lipid lowering
Number of subjects: 150
Study 30372084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg IR tablet
Number of subjects: 20
Study 30372084 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological variables (pH and postdose phase III contractions)
Number of subjects: 20
Study 30372084 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis of plasma profiles
Number of subjects: 20
Study 26686818 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior (TPB)
Number of subjects: 100
Study 26686818 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' perceived behavioral control
Number of subjects: 100
Study 26686818 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents' subjective norms
Number of subjects: 100
Study 26686818 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to limit SSB consumption
Number of subjects: 100
Study 26686818 — intervention group
Group type: EXPERIMENTAL
Intervention: TPB
Number of subjects: 100
Study 26686818 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents' intention to limit SSB consumption
Number of subjects: 100
Study 24841265 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 10030
Study 24841265 — intervention group
Group type: COMPARATOR
Intervention: Non-chlorhexidine groups
Number of subjects: 10030
Study 24841265 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-resistant isolates
Number of subjects: 10030
Study 22191994 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue-holding swallow (THS) group (THSG) performed the tongue‐holding manoeuvre every 5s for 20min for 20 sessions over 4 weeks.
Number of subjects: 20
Study 22191994 — intervention group
Group type: COMPARATOR
Intervention: Normal swallow group (control) swallowed without tongue‐holding for the same length of time.
Number of subjects: 20
Study 20589148 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin treatment for thromboembolic complications
Number of subjects: 63
Study 20589148 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin treatment for haemorrhagic complications
Number of subjects: 63
Study 20589148 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched controls for thromboembolic complications)
Number of subjects: 63
Study 20589148 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched controls for haemorrhagic complications)
Number of subjects: 63
Study 20589148 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemorrhagic cases
Number of subjects: 63
Study 17342693 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B 12 for two months followed by folic acid for two months
Number of subjects: 74
Study 17342693 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid for two months followed by Vitamin B 12 for two months
Number of subjects: 74
Study 17342693 — intervention group
Group type: EXPERIMENTAL
Intervention: Washout period after treatment
Number of subjects: 74
Study 17342693 — intervention group
Group type: EXPERIMENTAL
Intervention: End of study measurements
Number of subjects: 74
Study 14665555 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml of gelatin colloid solution intravenously before surgery
Number of subjects: 396
Study 14665555 — intervention group
Group type: COMPARATOR
Intervention: Conventional i.v. fluid regime with a crystalloid solution (saline)
Number of subjects: 396
Study 11703374 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART with plasma HIV-1 RNA suppressed to below 500 copies/ml (group 1)
Number of subjects: 355
Study 11703374 — intervention group
Group type: COMPARATOR
Intervention: HAART with at least one viral rebound (group 2)
Number of subjects: 355
Study 9204846 — intervention group
Group type: COMPARATOR
Intervention: Clean dressing technique
Number of subjects: 30
Study 9204846 — intervention group
Group type: COMPARATOR
Intervention: Sterile dressing technique
Number of subjects: 30
Study 7703514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileo-rectal anastomosis (IRA)
Number of subjects: 74
Study 3295629 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen section examinations on axillary lymph nodes
Number of subjects: 162
Study 29365294 — intervention group
Group type: EXPERIMENTAL
Intervention: Solanezumab (400 mg, intravenously every 4 weeks for 76 weeks)
Number of subjects: 2129
Study 29365294 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenously every 4 weeks for 76 weeks)
Number of subjects: 2129
Study 29365294 — intervention group
Group type: EXPERIMENTAL
Intervention: Solanezumab
Number of subjects: 2129
Study 29365294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2129